BCG008 / Biocytogen - LARVOL DELTA

BCG008, a human Siglec-15 blocking antibody, displays potent anti-tumor activity in Siglec-15-humanized mice (AACR 2023) - "In safety evaluation, BCG008 was well-tolerated in the tumor-bearing mice; no adverse effects were observed even at high doses (e.g. 30 mg/kg). Taken together, these results demonstrate that BCG008 is a novel anti-human Siglec-15 blocking antibody with favorable efficacy and safety profiles that can provide potential benefits for future cancer immunotherapy."

IO biomarker • Preclinical • Oncology • CD4 • CD8 • SIGLEC15

Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022 (Businesswire) - "Biocytogen Pharmaceuticals...will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on October 24-26 and virtually on November 2-4, 2022....Dr. Vivian Tian, Sr. Director of Biocytogen Europe Innovation Center (BEIC), will give an oral presentation introducing Biocytogen’s pipeline assets and the progress of Project Integrum, highlighting the progress of several antibody programs, including TNFR2, B7-H3, CCR8, and Siglec-15."

Pipeline update • Oncology